Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both <i>in vitro</i> and <i>in vivo</i> models.

ABSTRACT: Recombinant chimeric horsepox virus (TNX-801) is a preclinical vaccine in development against mpox and smallpox. In this report, we investigated the potential phenotypic differences in in vitro and in vivo models between TNX-801 and older vaccinia virus (VACV)-based vaccine strains (VACV-Lis and VACV-NYCBH) used in the eradication of smallpox as well as VACV-WR, VACV-IHD, and MVA. TNX-801 displayed a small plaque phenotype (~1-2 mm) in BSC-40 and Vero-E6 cells. Multi-step replication kinetics in immortalized nonhuman primate cell lines, and human primary cells from dermal and respiratory tracts yielded >10- to 100-fold lower infectious titers than the VACV strains. In addition, the infectious particle-to-genome copy ratio data suggests that TNX-801 genome packaging is ~10- to

SUBMITTER: Trefry SV 

PROVIDER: S-EPMC11656774 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature